Becton Dickinson Acquires NAT Diagnostics
May 15, 2020
Becton Dickinson (BD) has acquired NAT Diagnostics, a molecular diagnostics firm that developed an isothermal NAT Dx technology for rapid point-of-care testing. BD plans to further develop the NAT Dx platform to offer decentralized molecular testing options targeted for early 2023, expanding BD’s capabilities in point-of-care molecular diagnostics.
- Buyers
- Becton Dickinson
- Targets
- NAT Diagnostics
- Industry
- Medical Devices
- Location
- California, United States
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
DCN Dx Acquires Biomed Diagnostics
April 25, 2022
Medical Devices
DCN Dx has completed its acquisition of Biomed Diagnostics, Inc., a microbiological testing products company based in White City, Oregon. The deal expands DCN Dx's point-of-use testing and sampling capabilities across human, veterinary, food safety and environmental markets by adding Biomed's InPouch/InTray culture and transport product lines.
-
Natera Acquires Foresight Diagnostics
December 11, 2025
Healthcare Services
Natera has completed its acquisition of Foresight Diagnostics for up to $450 million, consisting of $275 million upfront in stock and up to $175 million in revenue- and reimbursement-linked milestones. The deal brings Foresight’s ultrasensitive PhasED-Seq MRD and liquid-biopsy capabilities into Natera’s Signatera platform, strengthening Natera’s oncology and lymphoma diagnostics capabilities and accelerating clinical and biopharma partnerships.
-
R-Biopharm AG Acquires AusDiagnostics
June 7, 2022
Biotechnology
German biotechnology company R-Biopharm AG has acquired Australian molecular diagnostics manufacturer AusDiagnostics. The purchase adds AusDiagnostics' multiplex MT-PCR platforms, extraction reagents and laboratory automation capabilities to R-Biopharm's clinical diagnostics portfolio, supporting capability expansion and internationalization into new clinical, veterinary and applied testing markets.
-
Ott Scientific Acquires American Bionostica
April 1, 2021
Medical Devices
Ott Scientific has acquired American Bionostica, Inc., a developer and manufacturer of specialty lateral flow assays; the acquisition was effective April 1 and ABI will operate inside Ott Scientific’s Ethos Biosciences subsidiary. The American Bionostica team will join Ott Scientific, with expanded research and production capacity planned at Ott Scientific’s new ISO13485/cGMP space in Logan Township, New Jersey.
-
ICON plc Acquires MolecularMD Corporation
February 21, 2019
Healthcare Services
ICON plc acquired MolecularMD Corporation, a molecular diagnostic specialty laboratory, to expand ICON's molecular diagnostic testing capabilities—including next-generation sequencing and immunohistochemistry—and strengthen support for oncology drug–diagnostic co-development. The acquisition integrates MolecularMD's central laboratory services and client base into ICON's global laboratory network to support precision medicine programs across clinical development phases.
-
JMD Properties, Inc. Acquires Stella Diagnostics
September 2, 2020
Biotechnology
JMD Properties, Inc. announced the acquisition of Stella Diagnostics, LLC via a preferred stock transaction and will change its corporate name to Stella Diagnostics, Inc. The deal positions the public company to pivot into the molecular diagnostics / biotech sector to commercialize Stella’s oncology-focused assays for esophageal disease.
Track M&A activity that matters to you
Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.